Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day

Scandinavian Journal of Gastroenterology

Volumn 31, Issue 7, 1996, Pages 665-670

  Orskov C ^a   Wettergren, A ^b   Holst, J J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Appetite; gastric inhibitory polypeptide; glucagon like peptide 1; incretin; insulin; meal response

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; FEMALE; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0029765475     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609009147     Document Type: Article

References (48)

1. Jones IR, Owens DR, Sarsons DL, Bloom SR. Day profiles of glucose dependent insulinotropic polypeptide (GIP) in normal subjects. Horm Metab Res 1985;17:660-2.
2. Jorde R, Burhol PG, Waldum HL, Schulz TB, Lygren I, Florholmen J. Diurnal variation of plasma gastric inhibitory polypeptide in man. Scand J Gastroenterol 1980;15:617-9.
3. Salera M, Giacomoni P, Pironi L, Ustra C, Capelli M, Giougi A, et al. Circadian rhythm of gastric inhibitory polypeptide (GIP) in man. Metabolism 1983;32:21-4.
4. Ørskov C, Holst JJ, Poulsen SS, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987;30:874-81.
5. Kreymann B, Ghatei M, Williams G, Bloom SR. Glucagon-like peptide-1 (7-36) amide. A physiological incretin in man. Lancet 1987;2:1300-3.
6. Fieseler P, Bridenbaugh S, Nustede R, Martell J, Ørskov C, Holst JJ, et al. Physiological augmentation of amino-acid induced insulin secretion by gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), but not cholecystokinin (CCK-8) in normal man. Am J Physiol 1995;268: E949-55.
7. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-1.
8. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973;37:826-8.
9. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1 (7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76: 912-7.
10. Nauck MA, Busing M, Ørskov C, Siegel EG, Talartschik J, Baartz A, et al. Preserved incretin effect of immunoreactive gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) after oral glucose in type-1-diabetic patients with endstage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol 1993;30:36-45.
11. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, and peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35.
12. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7.
13. Albano JDM, Ekins RP, Maritz G, Turner RC. A sensitive precise radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol 1972;70:487-509.
14. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-8.
15. Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression. In: Methods in neurosciences. New York: Academic Press, 1991:3-22.
16. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, et al. Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 1983;56:1306-12.
17. Moody AJ, Jørgensen KD, Thim L. Structure-function relationships in porcine GIP. Diabetologia 1981;21:306.
18. Moody AJ, Krarup T, Larsen UD. Reactivity of anti-porcine gastric inhibitory polypeptide (GIP) rabbit antiserum R65 with synthetic human and porcine GIP. Scand J Clin Lab Invest 1992;52:103-6.
19. Krarup T, Holst JJ, Larsen KL. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 1985;249:E195-200.
20. Ørskov C, Rabenhøj L, Kofod H, Wettergren A. Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994;43: 535-9.
21. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 1994;107:1848-55.
22. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22:283-91.
23. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992;35:701-11.
24. Miholic J, Ørskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991;36:1361-70.
25. Herrmann C, Göke R, Richter G, Fehmann H-C, Arnold R. Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117-26.
26. Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinol 1991;128:3175-3182.
27. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993;133:233-40.
28. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 (GLP-1) 7-36 amide and peptide YY from the L-cell in the ileal mucosa are potent inhibitors of vagally induced gastric acid in man. Scand J Gastroenterol 1994;29:501-5.
29. Nauck MA, Siemsglüss J, Ørskov C, Holst JJ. Release of GLP-1 (7-36 amide) after oral glucose in patients with upper and lower gut resections [abstract]. Gut 1995. In press.
30. Holst JJ, Schwanz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H. Diurnal profile of pancreatic polypeptide, pancreatic glucagon. gut glucagon and insulin in human morbid obesity, Int J Obesity 1982;7:529-38.
31. Holst JJ, Ørskov C. Glucagon and other proglucagon-derived peptides. In: Walsh JH, Dockray GJ, editors. Gut peptides. New York: Raven Press, 1994:305-40.
32. Valverde I, Alarcon C, Ruiz-Grande C, Rovira A. Plasma glucagon and glucagon-like immunoreactivity in totally pancreatectomized humans. In: Tiengo A, editor. Diabetes secondary to pancreatopathy. Amsterdam: Excerpta Medica, 1988: 51-62.
33. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 1991;87:415-23.
34. Holst JJ. Degradation of glucagons. In: Henriksen JH, editor. Degradation of bioactive substances: physiology and pathophysiology. Boca Raton (FL): CRC Press, 1991:167-80.
35. Ørskov C, Wettergren A, Holst JJ. The metabolic rate and the biological effects of GLP-1 7-36 amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes 1993; 42:658-61.
36. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann G, et al. Is GLP-1 (9-36) amide an endogenous antagonist at GLP-1 receptors? [abstract]. Digestion 1994;55: 302.
37. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Ørskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994;269:18,827-33.
38. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: postprandial and 24-h secretion patterns. J Endocrinol 1993;138:159-66.
39. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988;9:122-34.
40. Krarup T, Groop P-H. Physiology and pathophysiology of GIP: a review. Scand J Clin Lab Invest 1991;51:571-9.
41. O'Dorisio TM, Sirinek KR, Mazzaferri EL, Cataland S. Renal effects of serum gastric inhibitory polypeptide (GIP). Metabolism 1977;26:651-6.
42. Sarson DL, Hayter RC, Bloom SR. The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man. Eur J Clin Invest 1982;12:457-61.
43. 2 fragment with potent pancreatic amylase inhibitory activity? Regul Pept 1992;39:9-17.
44. Lauritsen KB, Holst JJ, Moody AJ. Depression of insulin release by anti-GIP serum after oral glucose in rats. Scand J Gastroenterol 1981;16:417-20.
45. Ebert R. Gut signals for islet hormone release. Eur J Clin Invest 1990;20 Suppl 1:S20-6.
46. Lauritsen KB, Moody AJ, Christensen KC, Jensen SL. Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. Scand J Gastroenterol 1980;15:833-40.
47. Kolligs F, Fehmann H-C, Göke R, Göke B. Reduction of the incretin effect in rats by the GLP-1 receptor antagonist exendin (9-39) amide. Diabetes 1995. In press.
48. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR. Glucagon-like peptide-1 is a physiological ineretin in rat. J Clin Invest 1995;95:417-22.